Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin–piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia
<strong>Background<br></strong> Dihydroartemisinin–piperaquine has been Indonesia’s first-line anti-malarial treatment since 2008. Annual therapeutic efficacy studies (TES) done in the last 12 years showed continued high treatment efficacy in uncomplicated Plasmodium falciparum mal...
Main Authors: | Rahmasari, FV, Asih, PBS, Rozi, IE, Wangsamuda, S, Risandi, R, Dewayanti, FK, Permana, DH, Syahrani, L, Prameswari, HD, Basri, HH, Bustos, MDG, Charunwatthana, P, Dondorp, AM, Imwong, M, Syafruddin, D |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2023
|
Similar Items
-
Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin–piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia
by: Farindira Vesti Rahmasari, et al.
Published: (2023-08-01) -
Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia
by: Rahmasari, FV, et al.
Published: (2022) -
Efficacy and safety of dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia
by: Puji B. S. Asih, et al.
Published: (2022-03-01) -
Efficacy and safety of dihydroartemisinin-piperaquine.
by: Myint, H, et al.
Published: (2007) -
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.
by: Awab, G, et al.
Published: (2010)